B+
Bull case
25%
Probability
Target price
$205.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
PODD
InsuletANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$172.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$130.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+92.0
Score
AI commentary
News flow is earnings-heavy and operationally positive, but the market reaction has been less supportive than the print itself. The anchor close was $160.4 on 2026-05-07, while live price data showed PODD at $154.16 on 2026-05-08, implying that the T+3 reaction remained weak even after the revenue beat and raised outlook. Trusted follow-up coverage emphasized the raised 2026 revenue view and international Omnipod strength, while available analyst-revision snippets pointed to lower price targets rather than a broad post-print upgrade cycle. Peer context is now anchored to diabetes-technology comparators rather than broad health-care-services names, but the memo remains tentative because direct public pure-play comps are limited and Insulet's valuation still depends on product-cycle execution. No usable social dataset was provided, so confidence should rest mainly on filings and company materials.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-05-06catalystQ1 beat-and-raise confirmed in earnings releaseMedium impact
Insulet reported Q1 2026 revenue of $761.7 million, up 33.9%, with adjusted EPS of $1.42, exceeded its prior constant-currency growth guide, and raised FY2026 total revenue growth guidance to 21%-23% from 20%-22% [#8-K-2026-05-06].
2026-06-30catalystInternational Omnipod growth and algorithm rollout remain the main operating follow-throughHigh impact
International Omnipod revenue grew 59.4% reported and 45.2% in constant currency; the company also highlighted launches in five Middle East countries and a broader Omnipod 5 algorithm rollout expected in the coming weeks, which supports continued installed-base expansion [#8-K-2026-05-06].
2027-12-31eventEVOLVE pivotal study could extend type 2 diabetes platform optionalityHigh impact
Management said the first participant was enrolled in the EVOLVE pivotal study for a fully closed-loop AID system for adults with type 2 diabetes, supporting a planned 510(k) filing in 2027 [#8-K-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology